Regional Analysis

Global Rabies Vaccine Market – Regional Analysis

Regional segmentation of the global rabies vaccine market includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is projected to dominate the global rabies vaccines market with the largest share during the forecast period. The rising investments by governments in the public sector, as well as programs to eradicate rabies are favouring growth of the market in the region. For instance, countries in North America in 2008 established the North America Rabies Management Plan, by assessing and defining the needs, priorities to control rabies and eventually eliminate it from Canada, Mexico, and the U.S.

According to the European Centre for Disease Prevention and Control, in 2014 only 3 cases of rabies were reported in Europe, whereas Europe being the highest vaccine manufacturer for rabies. Key market players in Europe are GlaxoSmithKline, Sanofi–Pasteur and Novartis AG.

Furthermore, the market in Asia Pacific is expected to witness significant growth owing to active involvement by manufacturers in Asia Pacific countries such as China, Japan and India regarding development of innovative rabies vaccine and its substitutes. In February 2018, BioNote, Inc., a South Korean veterinary diagnostic company operating in rabies diagnostics, announced the launch of a new immune-fluorescent device, Vcheck, which can measure diagnostic result values with the help of fluorescent materials which help in detecting the zoonotic disease in animals.

The market in Asia Pacific is expected to witness new entrants and is a major competitive market due to the burden of rabies. According to data published by the World Health Organization (WHO) in 2017, India accounts for 59.9% of deaths due to rabies in Asia, and 35% of deaths globally. Major players operating in the region are Yisheng Biopharma, Serum Institute of India, Zuventus, and Bharat Biotech Ltd. Moreover companies such as Yisheng Laboratories and CPL Laboratories (India) have vaccine candidates in clinical trials.

Geographies Covered: